512 related articles for article (PubMed ID: 31196136)
1. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
[TBL] [Abstract][Full Text] [Related]
2. SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein-Dependent Apoptotic Pathway.
Ran LK; Chen Y; Zhang ZZ; Tao NN; Ren JH; Zhou L; Tang H; Chen X; Chen K; Li WY; Huang AL; Chen J
Clin Cancer Res; 2016 Jul; 22(13):3372-82. PubMed ID: 26861461
[TBL] [Abstract][Full Text] [Related]
3. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and molecular analysis of SIRT7 in hepatocellular carcinoma.
Yanai M; Kurata M; Muto Y; Iha H; Kanao T; Tatsuzawa A; Ishibashi S; Ikeda M; Kitagawa M; Yamamoto K
Pathology; 2020 Aug; 52(5):529-537. PubMed ID: 32586688
[TBL] [Abstract][Full Text] [Related]
5. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b.
Kim JK; Noh JH; Jung KH; Eun JW; Bae HJ; Kim MG; Chang YG; Shen Q; Park WS; Lee JY; Borlak J; Nam SW
Hepatology; 2013 Mar; 57(3):1055-67. PubMed ID: 23079745
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
7. Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation.
Liu L; Chen X; Xie S; Zhang C; Qiu Z; Zhu F
Hepatology; 2012 Nov; 56(5):1760-9. PubMed ID: 22576474
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
[TBL] [Abstract][Full Text] [Related]
10. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
11. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA 00607 as a tumor suppressor by modulating NF-κB p65/p53 signaling axis in hepatocellular carcinoma.
Sun QM; Hu B; Fu PY; Tang WG; Zhang X; Zhan H; Sun C; He YF; Song K; Xiao YS; Sun J; Xu Y; Zhou J; Fan J
Carcinogenesis; 2018 Dec; 39(12):1438-1446. PubMed ID: 30169594
[TBL] [Abstract][Full Text] [Related]
14. Regulatory factor X5 promotes hepatocellular carcinoma progression by transactivating tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta and suppressing apoptosis.
Chen DB; Zhao YJ; Wang XY; Liao WJ; Chen P; Deng KJ; Cong X; Fei R; Wu X; Shao QX; Wei L; Xie XW; Chen HS
Chin Med J (Engl); 2019 Jul; 132(13):1572-1581. PubMed ID: 31188160
[TBL] [Abstract][Full Text] [Related]
15. Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma.
Chen Y; Yang S; Hu J; Yu C; He M; Cai Z
PLoS One; 2016; 11(5):e0154939. PubMed ID: 27183310
[TBL] [Abstract][Full Text] [Related]
16. Pseudogene PDIA3P1 promotes cell proliferation, migration and invasion, and suppresses apoptosis in hepatocellular carcinoma by regulating the p53 pathway.
Kong Y; Zhang L; Huang Y; He T; Zhang L; Zhao X; Zhou X; Zhou D; Yan Y; Zhou J; Xie H; Zhou L; Zheng S; Wang W
Cancer Lett; 2017 Oct; 407():76-83. PubMed ID: 28823960
[TBL] [Abstract][Full Text] [Related]
17. CYP2E1-dependent upregulation of SIRT7 is response to alcohol mediated metastasis in hepatocellular carcinoma.
Zhang C; Zhao J; Zhao J; Liu B; Tang W; Liu Y; Huang W; Weinman SA; Li Z
Cancer Gene Ther; 2022 Dec; 29(12):1961-1974. PubMed ID: 35902730
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
[TBL] [Abstract][Full Text] [Related]
19. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
Giovannini C; Gramantieri L; Chieco P; Minguzzi M; Lago F; Pianetti S; Ramazzotti E; Marcu KB; Bolondi L
J Hepatol; 2009 May; 50(5):969-79. PubMed ID: 19304334
[TBL] [Abstract][Full Text] [Related]
20. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Zhang ZY; Hong D; Nam SH; Kim JM; Paik YH; Joh JW; Kwon CH; Park JB; Choi GS; Jang KY; Park CK; Kim SJ
J Hepatol; 2015 Jan; 62(1):121-30. PubMed ID: 25131770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]